Bradykinin (acetate)
(Synonyms: 缓激肽乙酸盐,H 1970) 目录号 : GC13506
An endogenous vasodilator
Cas No.:6846-03-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bradykinin (acetate) is a well-known 9-amino acid endogenous vasoactive peptide and a systemic vasodilator [1].
Bradykinin is a potent endothelium-dependent vasodilator, leading to the reduction in blood pressure. It also induces contraction of non-vascular smooth muscle in the bronchus and gut, increases vascular permeability and is also involved in the mechanism of pain. Bradykinin is an inflammatory mediator. The Bradykinin B1 receptor is expressed only as a result of tissue injury and plays a role in inflammation. The Bradykinin B2 receptor is constitutively expressed and participates in bradykinin's vasodilatory role.
In cultured endothelial cells, bradykinin promoted a rapid dissociation of the eNOS:B2 receptor complex [2]. In the mouse gastrointestinal tract and pancreas, bradykinin stimulated extravasation from postcapillary venules by two- to sevenfold by interacting with B2 receptors and stimulating tachykinin release from sensory nerves [3].
In healthy men, bradykinin (100-3200 ng/kg min) dose-related increased plasma concentrations of 6-oxo-PGF1a , the stable hydrolysis product of prostacyclin (PGI2). So bradykinin may have a use as a probe of PG12 production in vivo in pathological states [1].
References:
[1]. Barrow SE, Dollery CT, Heavey DJ, et al. Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol. 1986 Jan;87(1):243-7.
[2]. Ju H, Venema VJ, Marrero MB, et al. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J Biol Chem. 1998 Sep 11;273(37):24025-9.
[3]. Figini M, Emanueli C, Grady EF, et al. Substance P and bradykinin stimulate plasma extravasation in the mouse gastrointestinal tract and pancreas. Am J Physiol. 1997 Apr;272(4 Pt 1):G785-93.
| Cas No. | 6846-03-3 | SDF | |
| 别名 | 缓激肽乙酸盐,H 1970 | ||
| 化学名 | (S)-2-((S)-2-((S)-1-((S)-2-((S)-2-(2-((S)-1-((S)-1-((S)-2-amino-5-guanidinopentanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)-3-phenylpropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanamido)-5-guanidinopentanoic a | ||
| Canonical SMILES | O=C([C@H](CCC1)N1C([C@@H](N)CCCNC(N)=N)=O)N(CCC2)[C@@H]2C(NCC(N[C@H](C(N[C@@H](CO)C(N(CCC3)[C@@H]3C(N[C@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)CC4=CC=CC=C4)=O)=O)=O)CC5=CC=CC=C5)=O)=O.CC(O)=O | ||
| 分子式 | C50H73N15O11 • XC2H4O2 | 分子量 | 1120.3 |
| 溶解度 | ≥ 113 mg/mL in DMSO with gentle warming, ≥ 226.6 mg/mL in Water, ≥ 113.5 mg/mL in EtOH with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8926 mL | 4.4631 mL | 8.9262 mL |
| 5 mM | 0.1785 mL | 0.8926 mL | 1.7852 mL |
| 10 mM | 0.0893 mL | 0.4463 mL | 0.8926 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet